Vasomedical raises $2.5m:
This article was originally published in Clinica
Executive Summary
Westbury, New York-based Vasomedical has closed a $2.5m round of private financing. It will use the proceeds for marketing efforts relating to the use of its EECP external counterpulsation therapy as treatment for congestive heart failure patients; for activities to expand reimbursement coverage with third-party payers; and for the further promotion of EECP therapy in the current refractory angina market segment. The EECP system is designed as a noninvasive method to increase circulation in the heart and restore systemic vascular function.